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Aberrant phosphorylation of tau protein on serine and threonine residues has been shown to be critical in neurodegenerative disorders called
tauopathies. An increasing amount of data suggest that tyrosine phosphorylation of tau might play an equally important role in pathology, with at
least three putative tyrosine kinases of tau identified to date. It was recently shown that the tyrosine kinase Syk could efficiently phosphorylate
α-synuclein, the aggregated protein found in Parkinson's disease and other synucleinopathies. We report herein that Syk is also a tau kinase,
phosphorylating tau in vitro and in CHO cells when both proteins are expressed exogenously. In CHO cells, we have also demonstrated by co-
immunoprecipitation that Syk binds to tau. Finally, by site-directed mutagenesis substituting the tyrosine residues of tau with phenylalanine, we
established that tyrosine 18 was the primary residue in tau phosphorylated by Syk. The identification of Syk as a common tyrosine kinase of
both tau and α-synuclein may be of potential significance in neurodegenerative disorders and also in neuronal physiology. These results bring
another clue to the intriguing overlaps between tauopathies and synucleinopathies and provide new insights into the role of Syk in neuronal
physiology.
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intracellular inclusions of highly insoluble proteins, and a
classification based upon the main protein component of these
aggregates is widely used. The term “synucleinopathies”, for
instance, refers to a group of disorders including Parkinson's
disease (PD) in which the synaptic protein α-synuclein (α-syn)
forms neuronal or glial aggregates [1]. “Tauopathies” are
another pathological entity in which the microtubule-associated
protein tau self-assembles into filamentous inclusions called
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Open access under CC BY license.Alzheimer's disease (AD), progressive supranuclear palsy and
corticobasal degeneration.
Human brain tau consists of a family of six isoforms,
generated by the alternative splicing of a single mRNA
transcript. Tau proteins contain either three (tau 3R) or four
(tau 4R) tubulin-binding domains depending on the splicing of
exon 10, and either one (tau 1N) two (tau 2N) or no (tau 0N) N-
terminal inserts depending on the inclusion of exon 2, exons 2
and 3, or exclusion of both, respectively. Their apparent
molecular weights range from 45 kDa for tau 0N3R isoform to
65 kDa for tau 2N4R. When aggregated in NFT, tau is
abnormally hyperphosphorylated by a series of serine/threonine
kinases, among which glycogen synthase kinase-3β, cyclin-
dependent kinase 5 and casein kinase 1 appear to be the most
Fig. 1. Phosphorylation of tau by Syk in vitro. Recombinant tau 2N4R was
expressed in E. coli BL21 (DE3) and purified as described previously [21].
Recombinant human tau (2 μg)was incubatedwith or without 0.4μg of Syk or Abl
(Invitrogen) in 30 μl of kinase buffer (50 mMHepes pH 7.4, 5 mMMnCl2, 5 mM
MgCl2, 0.01% (v/v) Triton X-100, 12 mM beta-glycerophosphate and 1 mM
dithiothreithiol) in the presence of 0.2 M ATP for 30 min at 30 °C. 30 μl of SDS-
PAGE sample buffer was added to stop the reaction. Control tau was put through
the same procedure but without kinase. The phosphorylation reactions were
analyzed by Western blotting using 8% gels and P-Tyr-100 (Blot P-Tyr) and tau-5
(Blot Tau). The data presented are representative of three independent experiments.
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sphorylation contributes to neurodegeneration through the
destabilisation of microtubules [5].Fig. 2. Phosphorylation of tau by Syk in cells. (A) CHO cells were co-transfectedwith 2
Abl (Tau+Abl) or empty vector (Tau+pEGFP-N2) as described previously. An addi
(Tau pervanadate). Cells were harvested after 24 h and tau was immunoprecipitated us
P-Tyr-100 (IP V5, Blot P-Tyr) and with Tau-5 (IP V5, Blot Tau) or Syk N-19 (IP V5, B
with 0N3R untagged human tau and native human Syk (Tau 0N3R+Syk) or transfect
immunoprecipitated using tau-5 antibody. Western blots on the immunoprecipitates w
data presented are representative of three independent experiments and were confirmRecent data suggest that phosphorylation of tau also occurs
on tyrosine residues and this could be of potential significance
in pathological conditions [6,7]. Human tau protein possesses
five tyrosine residues on positions 18, 29, 197, 310 and 394
(numbered according to the longest 2N4R tau isoform). Tau
extracted from NFT of AD patients was found to be
phosphorylated on tyrosine 18 (Y18) by immunocytochemistry
using a phosphospecific antibody [6], and on tyrosine 394
(Y394) by mass spectrometry [8]. Tyrosine 197 (Y197) has
been shown to be phosphorylated in tau aggregates from
transgenic mice overexpressing mutant tau [9]. Recently, the
dual specificity kinase tau-tubulin kinase 1 has been shown to
phosphorylate tau in vitro on Y197 [10]. While Abl was
recently described as a candidate tyrosine kinase for Y394 [8],
Fyn is considered to be the kinase for Y18 [6].
The tyrosine kinase Syk is known for its critical role in
signalling through immune receptors in leucocytes [11]. Syk
tyrosine kinase expression is however not confined to
hematopoietic cells, and has been reported in a variety of
tissues [12]. Syk expression has been confirmed in the central
nervous system (CNS) by immunoblot analysis of mouse brain
homogenates, and its localization in mouse neuronal cytoplasm
affirmed by immunohistochemistry [12]. While its function in
the CNS remains unclear, Syk was recently found to be a kinase
for α-syn [13]. The direct interaction of Syk and α-syn was
proven by confocal microscopy and a dual-hybrid system
approach [13]. The intriguing overlap in the pathophysiology ofN4RV5 tagged human tau and constructs expressing Syk-GFP (Tau+Syk-GFP),
tional positive control consisted of tau-transfected cells treated with pervanadate
ing anti-V5 antibody. Western blots on the immunoprecipitates were probed with
lot Syk) after membrane stripping. (B) CHO cells were transiently co-transfected
ed with 0N3R tau alone (Tau 0N3R). Cells were harvested after 24 h and tau was
ere probed with P-Tyr-100 (IP Tau, Blot P-Tyr) and Tau-5 (IP Tau, Blot Tau). The
ed by using another phosphotyrosine antibody (4G10, Upstate, data not shown).
Fig. 3. Tyr-18 is the primary site phosphorylated by Syk in transfected CHO cells. CHO cells were transiently co-transfected with Syk-GFP construct and tau (Tau+
Syk-GFP) or Y18F mutant tau (Tau Y18F+Syk-GFP) or Y197F mutant tau (Tau Y197F+Syk-GFP) or Y394F mutant tau (Tau Y394F+Syk-GFP), in which tyrosine
18, 197 or 394 were replaced by phenylalanine. The constructs used were based upon tau 2N4R cDNA and were V5-tagged. Cells were harvested after 24 h and tau
was immunoprecipitated using anti-V5 antibody. Western blots of the immunoprecipitates were probed with P-Tyr-100 (IPV5, Blot P-Tyr) and Tau-5 (IPV5, Blot Tau).
The data presented are representative of three independent experiments and were confirmed by using another phosphotyrosine antibody (4G10, Upstate, data not
shown).
Fig. 4. Stoichiometry and time course of phosphate incorporation into tau
following phosphorylation with Syk (solid triangles) or Fyn (open squares).
Recombinant human tau (2 μg) was incubated with 30 μl of kinase buffer (as in
Fig. 1) in the presence of 0.2 M ATP and 5 μCi [γ-32P]ATP. Ten μl aliquots
were pipetted in duplicate onto p81 Whatman papers at the indicated times as
described previously [22]. The results are representative of two independent
experiments.
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whether tau protein was also a substrate for Syk tyrosine kinase
[14]. We herein report that Syk can phosphorylate Tau on Y18,
and that the kinase and its substrate directly interact.
We first investigated whether Syk can directly phosphorylate
tau in vitro. Recombinant human tau 2N4R was incubated with
or without recombinant Syk or Abl [8]. Tau was phosphorylated
in vitro by Syk and by its previously recognized tyrosine kinase
Abl as judged on Western blots probed with P-Tyr-100 anti-
phosphotyrosine antibody (Cell Signaling), whereas no phos-
phorylation was observed in experiments where tau was
incubated without Syk (Fig. 1). In the presence of Syk, an
additional band of approximately 70 kDa, migrating just above
tau, was observed on the phosphotyrosine immunoblot. This
band is likely to contain Syk since the kinase is known to
autophosphorylate. Taken together, these results demonstrate
that Syk can directly catalyze tau phosphorylation.
To determine whether Syk can phosphorylate tau in cells, co-
transfection experiments were performed in CHO cells using
Syk expression vectors together with untagged or V5-tagged
tau. Cells were lysed and tau was immunoprecipitated with
either anti-V5 antibody (Invitrogen) or with anti-tau antibody
(Tau-5, BD Biosciences). Western analysis was then performed
on immunoprecipitated tau using the anti-phosphotyrosine (P-
Tyr-100, Cell Signaling), anti-tau (Tau-5) or anti-Syk (N-19,
Santa Cruz) antibodies as previously described [8]. In
preliminary experiments, a V5-tagged tau 2N4R construct and
wild-type Syk were transiently coexpressed in CHO cells. We
have previously shown that V5-tagged tau 2N4R migrates atapproximately 70 kDa on SDS-PAGE [8]. Because of the close
molecular weights of Syk (72 kDa) and the V5-tau construct,
the two proteins co-migrated using conventional denaturing gel
electrophoresis (data not shown). To better resolve the two
proteins, we used two complementary approaches. In a first set
of experiments, we expressed V5-tagged tau 2N4R along with a
Syk-GFP construct that migrates at 100 kDa. The Syk-GFP
construct was proven to remain functionally active in previous
studies [15]. In a second set of experiments, we coexpressed
wild-type untagged Syk along with the shortest tau isoform
191T. Lebouvier et al. / Biochimica et Biophysica Acta 1783 (2008) 188–192(0N3R), which migrates at 45 kDa. Tau protein was phos-
phorylated on tyrosine when co-transfected with Syk-GFP
construct or with its known tyrosine kinase Abl (Fig. 2A).
Additional positive controls included tau-transfected cells
treated with the tyrosine-phosphatase inhibitor pervanadate
(100 μM for 30 min). When Syk-GFP was co-transfected with
tau, tau immunoprecipitates contained a ∼100-kDa tyrosine-
phosphorylated protein, likely to contain Syk-GFP since this
enzyme is tyrosine phosphorylated (Fig. 2A). This was
confirmed by blotting with Syk antibody after membrane
stripping (Fig. 2A). This co-immunoprecipitation of Syk with
tau is indicative of Syk and its substrate being in the same
protein complex. In order to exclude any effects of the V5 and
GFP tags fused with tau and Syk, we wished to repeat this
experiment using vectors expressing native proteins. The
untagged and shortest isoform of tau (0N3R) was phosphory-
lated on tyrosine when co-transfected with native 72 kDa Syk
(Fig. 2B), as compared with the transfection of tau alone. As in
Fig. 2A, an additional 72-kDa band corresponding to phospho-
Syk was visible on the phosphotyrosine blot when Syk was co-
transfected with tau. The co-immunoprecipitation is therefore
confirmed with native proteins. Taken together, these results
demonstrate that Syk tyrosine kinase can both phosphorylate
and co-immunoprecipitate with tau in cells, consistent with the
direct phosphorylation of the substrate demonstrated in vitro
(Fig. 1). The binding of Syk to both the shortest and longest
isoform of tau suggests that it is independent of tau splicing.
Tau has been shown to be tyrosine phosphorylated on residue
18, 197 and 394 [6,8–10]. To map the tyrosine residue(s)
phosphorylated by Syk in tau, Syk was co-transfected into CHO
cells along with wild-type or mutant tau constructs in which
individual tyrosines were replaced by phenylalanine (Y18F,
Y197F and Y394F). These cDNA constructs have been
described in detail previously [8]. The only such tyrosine
mutation that resulted in a strong decrease in tau tyrosine
phosphorylation was Y18F (Fig. 3). Tyrosine phosphorylation
of the Y197F and Y394F constructs were not significantly
different from the wild-type control (Fig. 3). This clearly
demonstrates that Y18 is the major tyrosine phosphorylation site
for Syk. In addition, the binding of Syk was independent of the
tyrosine phosphorylation state of tau (Fig. 3), suggesting that the
SH2 domains of Syk are not involved in its binding to tau.
As Fyn and Syk phosphorylate the same tyrosine residue on
tau, we decided to perform a time course of phosphorylation of
tau by the two kinases under conditions designed to favour the
measurement of stoichiometry. After 30 min, Syk had
incorporated an average of 0.23 mol of phosphate/mol of tau
and Fyn had incorporated an average of 0.25 mol of phosphate/
mol of tau. These results show that Syk and Fyn phosphorylate
tau with the same efficacy (Fig. 4).
Our demonstration of binding of tau to Syk is consistent with
tau being a specific substrate for Syk and for their involvement
in a cell-signaling pathway in neurons. Interestingly, Syk plays
an important role in signalling events of neurite induction and
outgrowth in neuronal cell lines [16]. It is thus tempting to
speculate that the phosphorylation of tau by Syk could be
involved in neurite outgrowth. Our study also reinforces the roleof Syk in neurodegenerative disorders. Remarkably, Y18 has
been shown to be phosphorylated in NFT, suggesting that, like
Fyn, Syk could be critical in the pathophysiology of AD
[6,7,17]. Although early studies suggested a clear distinction
between ‘tauopathies’ and ‘synucleinopathies’, more recent
studies demonstrate that there is often an overlap in the
pathological findings in these disorders [18–20]. Syk binds to
and phosphorylates both tau and synuclein, suggesting that this
kinase could be a link between synucleinopathies and
tauopathies. In conclusion, our findings significantly contribute
to the understanding of the signaling pathways involving
tyrosine phosphorylation of tau in both physiological and
pathological conditions. Further elucidation of the functional
relationship between tau and the Syk in neurons could provide
critical insights into the role of tau in cell signaling as well as the
role of tau in neurodegenerative processes.
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